Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

The Lancet Regional Health - Europe, Journal Year: 2021, Volume and Issue: 10, P. 100208 - 100208

Published: Sept. 6, 2021

SARS-CoV-2 mRNA vaccines have proven high efficacy, however, limited data exists on the duration of immune responses and their relation to age side effects.We studied antibody memory T cell after two-dose BNT162b2 vaccine in 122 volunteers up 6 months correlated findings with found a robust response Spike protein second dose. However, levels declined at 12 weeks post-vaccination, indicating waning over time. At dose, were similar persons vaccinated one dose or COVID-19 convalescent individuals. The antibodies efficiently blocked ACE2 receptor binding five variants concern week but this was decreased three months. 87% individuals developed Spike-specific responses, which lower increased proportions immunosenescent CD8+ TEMRA cells. We correlate negatively positively total score vaccination effects.The induces strong VOCs 1 post-vaccination that decreases thereafter. although detectable majority, higher immunosenescence. deterioration suggests need monitor for potential booster vaccination.

Language: Английский

---

COVID-19 vaccine development: milestones, lessons and prospects

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: May 3, 2022

Abstract With the constantly mutating of SARS-CoV-2 and emergence Variants Concern (VOC), implementation vaccination is critically important. Existing vaccines mainly include inactivated, live attenuated, viral vector, protein subunit, RNA, DNA, virus-like particle (VLP) vaccines. Viral vector vaccines, subunit mRNA may induce additional cellular or humoral immune regulations, including Th cell responses germinal center responses, form relevant memory cells, greatly improving their efficiency. However, some be associated with complications like thrombocytopenia myocarditis, raising concerns about safety these COVID-19 Here, we systemically assess efficacy possible different effects on pregnant women, elderly, people diseases acquired immunodeficiency syndrome (AIDS), transplant recipients, cancer patients. Based current analysis, governments agencies are recommended to continue advance vaccine immunization process. Simultaneously, special attention should paid health status timely treatment complications, development, ensuring lives In addition, available measures such as mix-and-match vaccination, developing new nanoparticle optimizing adjuvant improve could considered.

Language: Английский

---

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Journal of Hepatology, Journal Year: 2021, Volume and Issue: 75(2), P. 435 - 438

Published: April 21, 2021

Two SARS-CoV-2 mRNA vaccines were approved to prevent COVID-19 infection, with reported vaccine efficacy of 95%. Liver transplant (LT) recipients are at risk lower immunogenicity and not included in the registration trials. We assessed safety this special population.

Language: Английский

---

Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine

The Lancet Regional Health - Europe, Journal Year: 2021, Volume and Issue: 9, P. 100178 - 100178

Published: July 23, 2021

Dialysis and kidney transplant patients are vulnerable populations for COVID-19 related disease mortality.

Language: Английский

---

SARS-CoV-2, COVID-19 and the aging immune system

Nature Aging, Journal Year: 2021, Volume and Issue: 1(9), P. 769 - 782

Published: Sept. 14, 2021

Language: Английский

---

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

The Lancet Infectious Diseases, Journal Year: 2021, Volume and Issue: 21(11), P. 1529 - 1538

Published: June 23, 2021

BackgroundThe effectiveness of SARS-CoV-2 vaccines in older adults living long-term care facilities is uncertain. We investigated the protective effect first dose Oxford-AstraZeneca non-replicating viral-vectored vaccine (ChAdOx1 nCoV-19; AZD1222) and Pfizer-BioNTech mRNA-based (BNT162b2) residents terms PCR-confirmed infection over time since vaccination.MethodsThe VIVALDI study a prospective cohort that commenced recruitment on June 11, 2020, to investigate transmission, outcomes, immunity staff England provide residential or nursing for aged 65 years older. In this study, we included facility undergoing routine asymptomatic testing between Dec 8, 2020 (the date was deployed facility), March 15, 2021, using national data linked within COVID-19 Datastore. Using Cox proportional hazards regression, estimated relative hazard PCR-positive at 0–6 days, 7–13 14–20 21–27 28–34 35–48 49 days beyond after vaccination, comparing unvaccinated vaccinated person-time from same residents, adjusting age, sex, previous infection, local incidence, bed capacity, clustering by facility. also compared mean PCR cycle threshold (Ct) values positive swabs obtained before vaccination. The registered with ISRCTN, number 14447421.Findings10 412 home 310 LTCFs were analysis. median participant age 86 (IQR 80–91), 7247 (69·6%) 10 female, 1155 (11·1%) had evidence infection. 9160 (88·0%) received least one dose, whom 6138 (67·0%) ChAdOx1 3022 (33·0%) BNT162b2. Between there 36 352 results 670 628 person-days, 1335 infections (713 612 residents) included. Adjusted ratios (HRs) declined 28 0·44 (95% CI 0·24–0·81) 0·38 (0·19–0·77) days. Similar sizes seen (adjusted HR 0·32, 95% 0·15–0·66) BNT162b2 (0·35, 0·17–0·71) Mean Ct higher occurred vaccination than those occurring (31·3 [SD 8·7] 107 tests vs 26·6 [6·6] 552 tests; p<0·0001).InterpretationSingle-dose provides substantial protection against 4–7 weeks might reduce transmission. However, risk not eliminated, highlighting ongoing need non-pharmaceutical interventions prevent transmission facilities.FundingUK Government Department Health Social Care.

Language: Английский

---

Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

Annals of the Rheumatic Diseases, Journal Year: 2021, Volume and Issue: 80(10), P. 1317 - 1321

Published: June 18, 2021

The registration trials of messenger RNA (mRNA) vaccines against SARS-CoV-2 did not address patients with inflammatory rheumatic diseases (IRD).To assess the humoral response after two doses mRNA vaccine SARS-CoV-2, in IRD treated immunomodulating drugs and impact on activity.Consecutive at rheumatology institute, who received their first (Pfizer) vaccine, were recruited to study, routine visit. They reassessed 4-6 weeks receiving second dose blood samples obtained for serology. activity assessment side effects documented during both visits. IgG antibodies (Abs) detected using II Quant (Abbott) assay.Two hundred sixty-four stable disease, (mean(SD) age 57.6 (13.18) years, disease duration 11.06 (7.42) years), recruited. immunomodulatory therapy was modified before or vaccination. After vaccination, 227 (86%) mounted Ab (mean (SD) 5830.8 (8937) AU/mL) 37 (14%) not, 22/37 B cell-depleting agents. reported minor. remained all patients.The vast majority developed a significant following administration Pfizer virus. Only minor no apparent noted.

Language: Английский

---

Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland

Vaccines, Journal Year: 2021, Volume and Issue: 9(11), P. 1286 - 1286

Published: Nov. 5, 2021

COVID-19 vaccinations are essential to mitigate the pandemic and prevent severe SARS-CoV-2 infections. However, serum antibody levels in vaccinated individuals gradually decrease over time, while is undergoing an evolution toward more transmissible variants, such as B.1.617.2, ultimately increasing risk of breakthrough infections further virus spread. This cross-sectional online study adult Poles (n = 2427) was conducted September 2021 (before a general recommendation administer booster vaccine dose Poland issued) assess attitude who completed current vaccination regime potential identify factors that may influence it. Overall, 71% participants declared willingness receive dose, with low median level fear receiving it 1.0 (measured by 10-point Likert-type scale), which increased particularly those having worse experience (in terms severity side effects associated fear) past vaccination. The lowest frequency (26.7%) seen group previously Ad26.COV2.S. majority mRNA vaccines wished same vaccine, case AZD1222, accordance observed only 9.1%. main reasons against accepting included experienced after previous doses, opinion unnecessary, safety uncertainties. Women, older (≥50 years), subjects obesity, chronic diseases, pre-vaccination post-vaccination infections, history influenza were significantly frequently willing dose. Moreover, immunosuppressed (88%) additional results emphasize some hesitancy studied indicate groups be targeted effective science communication regarding doses.

Language: Английский

---

Population antibody responses following COVID-19 vaccination in 212,102 individuals

Nature Communications, Journal Year: 2022, Volume and Issue: 13(1)

Published: Feb. 16, 2022

Population antibody surveillance helps track immune responses to COVID-19 vaccinations at scale, and identify host factors that may affect production. We analyse data from 212,102 vaccinated individuals within the REACT-2 programme in England, which uses self-administered lateral flow tests sequential cross-sectional community samples; 71,923 (33.9%) received least one dose of BNT162b2 vaccine 139,067 (65.6%) ChAdOx1. For both vaccines, positivity peaks 4-5 weeks after first then declines. At 21 days second BNT162b2, close 100% respondents test positive, while for ChAdOx1, this is significantly reduced, particularly oldest age groups (72.7% [70.9-74.4] ages 75 years above). decreases with age, higher females those previous infection. Antibody lower transplant recipients, obese individuals, smokers specific comorbidities. These will benefit additional doses.

Language: Английский

---

Flavonoids are promising safe therapy against COVID-19

Phytochemistry Reviews, Journal Year: 2021, Volume and Issue: 21(1), P. 291 - 312

Published: May 22, 2021

Flavonoids are a class of phenolic natural products, well-identified in traditional and modern medicines the treatment several diseases including viral infection. showed potential inhibitory activity against coronaviruses current pandemic outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) designated as COVID-19. Here, we have collected all data related to mechanisms flavonoids SARS-CoV-2 infection their significant immunomodulatory activities. The were mapped compared elect major with promising role pandemic. Further, linked global existence medicinal plants protection Computational analysis predicted that can exhibit binding essential targets required virus entry and/ or replication. also excellent anti-inflammatory activities inhibition various inflammatory cytokines. ability reduce exacerbation COVID-19 case obesity via promoting lipids metabolism. Moreover, high safety profile, suitable bioavailability, no adverse effects. For instance, rich globally distributed offer great from described this study strongly highlighted particularly quercetin luteolin multi-target SARS-CoV-2, which promote use expected future outbreaks. Therefore, regimen flavonoid-rich be recommended supplement sufficient amount for

Language: Английский

---